PortalPublikationenBaseline CTC Count as a Predictor of Long-Term Outcomes in H...

Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer

Standard

Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer. / Cieślikowski, Wojciech A; Milecki, Piotr; Świerczewska, Monika; Ida, Agnieszka; Kasperczak, Michał; Jankowiak, Agnieszka; Nowicki, Michał; Pantel, Klaus; Alix-Panabières, Catherine; Zabel, Maciej; Antczak, Andrzej; Budna-Tukan, Joanna.

in: J PERS MED, Jahrgang 13, Nr. 4, 608, 30.03.2023.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Cieślikowski, WA, Milecki, P, Świerczewska, M, Ida, A, Kasperczak, M, Jankowiak, A, Nowicki, M, Pantel, K, Alix-Panabières, C, Zabel, M, Antczak, A & Budna-Tukan, J 2023, 'Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer', J PERS MED, Jg. 13, Nr. 4, 608. https://doi.org/10.3390/jpm13040608

APA

Cieślikowski, W. A., Milecki, P., Świerczewska, M., Ida, A., Kasperczak, M., Jankowiak, A., Nowicki, M., Pantel, K., Alix-Panabières, C., Zabel, M., Antczak, A., & Budna-Tukan, J. (2023). Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer. J PERS MED, 13(4), [608]. https://doi.org/10.3390/jpm13040608

Vancouver

Cieślikowski WA, Milecki P, Świerczewska M, Ida A, Kasperczak M, Jankowiak A et al. Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer. J PERS MED. 2023 Mär 30;13(4). 608. https://doi.org/10.3390/jpm13040608

Bibtex

@article{4a6cbd6aa3c84d76a6365e2f442c2ce5,
title = "Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer",
abstract = "The aim of the present study was to verify whether the baseline circulating tumor cell (CTC) count might serve as a predictor of overall survival (OS) and metastasis-free survival (MFS) in patients with high-risk prostate cancer (PCa) during a follow-up period of at least 5 years. CTCs were enumerated using three different assay formats in 104 patients: the CellSearch{\textregistered} system, EPISPOT assay and GILUPI CellCollector. A total of 57 (55%) patients survived until the end of the follow-up period, with a 5 year OS of 66% (95% CI: 56-74%). The analysis of univariate Cox proportional hazard models identified a baseline CTC count ≥ 1, which was determined with the CellSearch{\textregistered} system, a Gleason sum ≥ 8, cT ≥ 2c and metastases at initial diagnosis as significant predictors of a worse OS in the entire cohort. The CTC count ≥ 1 was also the only significant predictor of a worse OS in a subset of 85 patients who presented with localized PCa at the baseline. The baseline CTC number did not affect the MFS. In conclusion, the baseline CTC count can be considered a determinant of survival in high-risk PCa and also in patients with a localized disease. However, determining the prognostic value of the CTC count in patients with localized PCa would optimally require longitudinal monitoring of this parameter.",
author = "Cie{\'s}likowski, {Wojciech A} and Piotr Milecki and Monika {\'S}wierczewska and Agnieszka Ida and Micha{\l} Kasperczak and Agnieszka Jankowiak and Micha{\l} Nowicki and Klaus Pantel and Catherine Alix-Panabi{\`e}res and Maciej Zabel and Andrzej Antczak and Joanna Budna-Tukan",
year = "2023",
month = mar,
day = "30",
doi = "10.3390/jpm13040608",
language = "English",
volume = "13",
journal = "J PERS MED",
issn = "2075-4426",
publisher = "MDPI Multidisciplinary Digital Publishing Institute",
number = "4",

}

RIS

TY - JOUR

T1 - Baseline CTC Count as a Predictor of Long-Term Outcomes in High-Risk Prostate Cancer

AU - Cieślikowski, Wojciech A

AU - Milecki, Piotr

AU - Świerczewska, Monika

AU - Ida, Agnieszka

AU - Kasperczak, Michał

AU - Jankowiak, Agnieszka

AU - Nowicki, Michał

AU - Pantel, Klaus

AU - Alix-Panabières, Catherine

AU - Zabel, Maciej

AU - Antczak, Andrzej

AU - Budna-Tukan, Joanna

PY - 2023/3/30

Y1 - 2023/3/30

N2 - The aim of the present study was to verify whether the baseline circulating tumor cell (CTC) count might serve as a predictor of overall survival (OS) and metastasis-free survival (MFS) in patients with high-risk prostate cancer (PCa) during a follow-up period of at least 5 years. CTCs were enumerated using three different assay formats in 104 patients: the CellSearch® system, EPISPOT assay and GILUPI CellCollector. A total of 57 (55%) patients survived until the end of the follow-up period, with a 5 year OS of 66% (95% CI: 56-74%). The analysis of univariate Cox proportional hazard models identified a baseline CTC count ≥ 1, which was determined with the CellSearch® system, a Gleason sum ≥ 8, cT ≥ 2c and metastases at initial diagnosis as significant predictors of a worse OS in the entire cohort. The CTC count ≥ 1 was also the only significant predictor of a worse OS in a subset of 85 patients who presented with localized PCa at the baseline. The baseline CTC number did not affect the MFS. In conclusion, the baseline CTC count can be considered a determinant of survival in high-risk PCa and also in patients with a localized disease. However, determining the prognostic value of the CTC count in patients with localized PCa would optimally require longitudinal monitoring of this parameter.

AB - The aim of the present study was to verify whether the baseline circulating tumor cell (CTC) count might serve as a predictor of overall survival (OS) and metastasis-free survival (MFS) in patients with high-risk prostate cancer (PCa) during a follow-up period of at least 5 years. CTCs were enumerated using three different assay formats in 104 patients: the CellSearch® system, EPISPOT assay and GILUPI CellCollector. A total of 57 (55%) patients survived until the end of the follow-up period, with a 5 year OS of 66% (95% CI: 56-74%). The analysis of univariate Cox proportional hazard models identified a baseline CTC count ≥ 1, which was determined with the CellSearch® system, a Gleason sum ≥ 8, cT ≥ 2c and metastases at initial diagnosis as significant predictors of a worse OS in the entire cohort. The CTC count ≥ 1 was also the only significant predictor of a worse OS in a subset of 85 patients who presented with localized PCa at the baseline. The baseline CTC number did not affect the MFS. In conclusion, the baseline CTC count can be considered a determinant of survival in high-risk PCa and also in patients with a localized disease. However, determining the prognostic value of the CTC count in patients with localized PCa would optimally require longitudinal monitoring of this parameter.

U2 - 10.3390/jpm13040608

DO - 10.3390/jpm13040608

M3 - SCORING: Journal article

C2 - 37108995

VL - 13

JO - J PERS MED

JF - J PERS MED

SN - 2075-4426

IS - 4

M1 - 608

ER -